Professor, Medicine, University of Miami School of Medicine
Hematology
Dr. Joyce M. Slingerland, MD
|
|
Give Review
Doctor Joyce M. Slingerland, MD is an expert in the field of Hematology. She has 3 awards "CMS Meaningful Use Stage 1 Certification", "Elected Member" and "Super Doctor". Joyce Slingerland is also a published physician. She has 85 publication published. The most recent publication is: Reduced expression of the cell cycle inhibitor p27Kip1 in non-small cell lung carcinoma: a prognostic factor independent of Ras. She is registered with Medicare and accepts Medicare payments.
Publications
- MAPK activation predicts poor outcome and the MEK inhibitor, selumetininb, reverses antiestrogen resistance in high grade serous ovarian cancer.
- Cytoplasmic p27 promotes epithelial-mesenchymal transition and tumor metastasis via STAT3-mediated Twist1 upregulation.
- Exosome transfer from stromal to breast cancer cells regulates therapy resistance pathways.
- ERα, SKP2 and E2F-1 form a feed forward loop driving late ERα targets and G1 cell cycle progression.
- Primary breast tumor-derived cellular models: characterization of tumorigenic, metastatic, and cancer-associated fibroblasts in dissociated tumor (DT) cultures.
- Links between oestrogen receptor activation and proteolysis: relevance to hormone-regulated cancer therapy.
- Triple negative breast cancer initiating cell subsets differ in functional and molecular characteristics and in γ-secretase inhibitor drug responses.
- PI3K/mTOR inhibition can impair tumor invasion and metastasis in vivo despite a lack of antiproliferative action in vitro: implications for targeted therapy.
- New insights on the role of hormonal therapy in ovarian cancer.
- ERα Phosphorylation at Y537 by Src Triggers E6-AP-ERα Binding, ERα Ubiquitylation, Promoter Occupancy, and Target Gene Expression.
- The physiology of integrated nuclear and extranuclear steroid signaling: Introductory comments.
- Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy.
- p27: a barometer of signaling deregulation and potential predictor of response to targeted therapies.
- Combined Src and ER blockade impairs human breast cancer proliferation in vitro and in vivo.
- p27 as Jekyll and Hyde: regulation of cell cycle and cell motility.
- RSK1 drives p27Kip1 phosphorylation at T198 to promote RhoA inhibition and increase cell motility.
- Combined Src and aromatase inhibition impairs human breast cancer growth in vivo and bypass pathways are activated in AZD0530-resistant tumors.
- Phosphorylation of p27Kip1 regulates assembly and activation of cyclin D1-Cdk4.
- mTOR-raptor binds and activates SGK1 to regulate p27 phosphorylation.
- Long-range activation of GREB1 by estrogen receptor via three distal consensus estrogen-responsive elements in breast cancer cells.
- Src promotes estrogen-dependent estrogen receptor alpha proteolysis in human breast cancer.
- Multiple roles of the PI3K/PKB (Akt) pathway in cell cycle progression.
- CRM1/Ran-mediated nuclear export of p27(Kip1) involves a nuclear export signal and links p27 export and proteolysis.
- Non-malignant and tumor-derived cells differ in their requirement for p27Kip1 in transforming growth factor-beta-mediated G1 arrest.
- PKB/Akt phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated G1 arrest.
- Altered p27(Kip1) phosphorylation, localization, and function in human epithelial cells resistant to transforming growth factor beta-mediated G(1) arrest.
- Regulation of the cell cycle by the ubiquitin pathway.
- The response of diffuse large cell and other intermediate grade non-Hodgkin''s lymphomas to adriamycin containing combination chemotherapy.
- Second malignant neoplasms in patients with non Hodgkin''s lymphoma.
- Overexpression of Akt converts radial growth melanoma to vertical growth melanoma.
- A Phase II trial of split, low-dose docetaxel and low-dose capecitabine: a tolerable and efficacious regimen in the first-line treatment of patients with HER2/neu-nega...
- Final results of a phase II study of nab-paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer.
- Transforming growth factor-beta and breast cancer: Introduction.
- Inhibition of the Rho GTPase, Rac1, decreases estrogen receptor levels and is a novel therapeutic strategy in breast cancer.
- Stem cell factor inhibits erythroid differentiation by modulating the activity of G1-cyclin-dependent kinase complexes: a role for p27 in erythroid differentiation cou...
- Skp2 is oncogenic and overexpressed in human cancers.
- p27 phosphorylation by Src regulates inhibition of cyclin E-Cdk2.
- p27 deregulation in breast cancer: prognostic significance and implications for therapy.
- Global protein shotgun expression profiling of proliferating mcf-7 breast cancer cells.
- Phase I/II trial of metronomic chemotherapy with daily dalteparin and cyclophosphamide, twice-weekly methotrexate, and daily prednisone as therapy for metastatic breas...
- Phase 2 study of neoadjuvant treatment with NOV-002 in combination with doxorubicin and cyclophosphamide followed by docetaxel in patients with HER-2 negative clinical...
- Regulation of the cdk inhibitor p27 and its deregulation in cancer.
- Overexpression of the integrin-linked kinase promotes anchorage-independent cell cycle progression.
- G1 control in mammalian cells.
- Reduced levels of the cell-cycle inhibitor p27Kip1 in epithelial dysplasia and carcinoma of the oral cavity.
- Involvement of p27Kip1 in G1 arrest by high dose 5 alpha-dihydrotestosterone in LNCaP human prostate cancer cells.
- The prognostic significance of altered cyclin-dependent kinase inhibitors in human cancer.
- Germline BRCA1/2 mutations and p27(Kip1) protein levels independently predict outcome after breast cancer.
- Reduction of Cdc25A contributes to cyclin E1-Cdk2 inhibition at senescence in human mammary epithelial cells.
- WW domain binding protein-2, an E6-associated protein interacting protein, acts as a coactivator of estrogen and progesterone receptors.
- The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestro...
- Deregulation of p27 by oncogenic signaling and its prognostic significance in breast cancer.
- Deregulation of the cell cycle in cancer.
- Transforming growth factor-beta and breast cancer: Cell cycle arrest by transforming growth factor-beta and its disruption in cancer.
- The roles of versican V1 and V2 isoforms in cell proliferation and apoptosis.
- UVB induced cell cycle checkpoints in an early stage human melanoma line, WM35.
- p16INK4A mediates cyclin dependent kinase 4 and 6 inhibition in senescent prostatic epithelial cells.
- Protein expression of the cell-cycle inhibitor p27Kip1 in malignant melanoma: inverse correlation with disease-free survival.
- Telomerase activity in prostate cancer, prostatic intraepithelial neoplasia, and benign prostatic epithelium.
- Prognostic implications of expression of the cell cycle inhibitor protein p27Kip1.
- Interleukin-6 dependent induction of the cyclin dependent kinase inhibitor p21WAF1/CIP1 is lost during progression of human malignant melanoma.
- Reduced expression of the cell cycle inhibitor p27Kip1 in non-small cell lung carcinoma: a prognostic factor independent of Ras.
- Cyclin E2: a novel CDK2 partner in the late G1 and S phases of the mammalian cell cycle.
- E-Cadherin-dependent growth suppression is mediated by the cyclin-dependent kinase inhibitor p27(KIP1).
- Loss of cyclin-dependent kinase inhibitor p27Kip1 is a novel prognostic factor in localized human prostate adenocarcinoma.
- Germline p16INK4A mutation and protein dysfunction in a family with inherited melanoma.
- Pulmonary manifestations of tuberous sclerosis in first degree relatives.
- Mutation of the p53 gene in human acute myelogenous leukemia.
- Transforming activity of mutant human p53 alleles.
- Transforming growth factor beta stabilizes p15INK4B protein, increases p15INK4B-cdk4 complexes, and inhibits cyclin D1-cdk4 association in human mammary epithelial cells.
- New functional activities for the p21 family of CDK inhibitors.
- Decreased levels of the cell-cycle inhibitor p27Kip1 protein: prognostic implications in primary breast cancer.
- TGF-beta mediated G1 arrest in a human melanoma cell line lacking p15INK4B: evidence for cooperation between p21Cip1/WAF1 and p27Kip1.
- Impact of the cyclin-dependent kinase inhibitor p27Kip1 on resistance of tumor cells to anticancer agents.
- UVB radiation induces p21Cip1/WAF1 and mediates G1 and S phase checkpoints.
- The transforming and suppressor functions of p53 alleles: effects of mutations that disrupt phosphorylation, oligomerization and nuclear translocation.
- A cell cycle-regulated inhibitor of cyclin-dependent kinases.
- A novel inhibitor of cyclin-Cdk activity detected in transforming growth factor beta-arrested epithelial cells.
- The energy sensing LKB1-AMPK pathway regulates p27(kip1) phosphorylation mediating the decision to enter autophagy or apoptosis.
- Tamoxifen may prevent both ER+ and ER- breast cancers and select for ER- carcinogenesis: an alternative hypothesis.
- PTEN deficiency: a role in mammary carcinogenesis.
- Constitutive MEK/MAPK activation leads to p27(Kip1) deregulation and antiestrogen resistance in human breast cancer cells.
- Down-regulation of p21WAF1/CIP1 or p27Kip1 abrogates antiestrogen-mediated cell cycle arrest in human breast cancer cells.
- The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy.
Schools
University Of Toronto Faculty Of Medicine
Princess Margaret Hospital
Toronto General Hospital
Wellesley Hospital
Doctors Specialties
- Internal Medicine
- Hematology
Accepted Insurances
Awards
- CMS Meaningful Use Stage 1 Certification
- Elected Member
- Super Doctor
Education
-
University of Toronto Faculty of Medicine
Hospital
-
University of Miami Hospital -
Miami Veterans Affairs Healthcare System
Drug Facts
| NPI NUMBER | 1700890282 | |
| NPPES Provider LastName | SLINGERLAND | |
| NPPES Provider FirstName | JOYCE | |
| NPPES Provider ZIPCode | 331361005 | |
| NPPES Provider State | FL | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 32.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1700890282 |
| Last Name Of The Provider | SLINGERLAND |
| First Name Of The Provider | JOYCE |
| View All |
Similar Doctors
|
|
Dr. Jo S. Reed, MD |
|
|
Dr. Roberto E. Sanchez, MD |
|
|
Dr. Jannelle Jurado, MD |
|
|
Dr. Darren R. Kaufman, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Thomas R. Lucero, MD |
|
|
Dr. Ricardo L. Perez, MD |
|
|
Dr. Denise L. Pereira, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Lawrence Negret, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Howard W. Wallach, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Myriam Landrin, MD
This Doctor is OpenDoctor Recommended.
|